Artelo Biosciences (ARTL)
1.41
-0.02 (1.40%)
Upcoming Events
Latest Headlines
Form 8-K ARTELO BIOSCIENCES, INC. For: May 26
May 27, 2026 4:40 PM - SEC Filing
Form PRE 14A ARTELO BIOSCIENCES, INC. For: Jul 17
May 26, 2026 5:04 PM - SEC Filing
Artelo Biosciences files $6.5M at-the-market offering prospectus
May 26, 2026 4:50 PM - StreetInsider
Form 424B5 ARTELO BIOSCIENCES, INC.
May 26, 2026 4:47 PM - SEC Filing
Form EFFECT ARTELO BIOSCIENCES, INC.
May 20, 2026 6:04 AM - SEC Filing
Form 424B5 ARTELO BIOSCIENCES, INC.
May 18, 2026 4:32 PM - SEC Filing
Artelo Biosciences terminates at-the-market offering agreement
May 15, 2026 4:03 PM - StreetInsider
Form 8-K ARTELO BIOSCIENCES, INC. For: May 11
May 15, 2026 4:01 PM - SEC Filing
Form SCHEDULE 13G ARTELO BIOSCIENCES, INC. Filed by: ARMISTICE CAPITAL, LLC
May 15, 2026 11:04 AM - SEC Filing
Form 10-Q ARTELO BIOSCIENCES, INC. For: Mar 31
May 14, 2026 4:08 PM - SEC Filing
Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results
May 14, 2026 4:05 PM - Globe NewsWire
Form S-3/A ARTELO BIOSCIENCES, INC.
May 14, 2026 4:01 PM - SEC Filing
Artelo Biosciences (ARTL) files $75M mixed shelf
May 4, 2026 4:47 PM - StreetInsider
Form S-3 ARTELO BIOSCIENCES, INC.
May 4, 2026 4:45 PM - SEC Filing
Artelo Biosciences partners with ScienceMachine for AI drug development
April 28, 2026 8:25 AM - StreetInsider
Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development
April 28, 2026 8:25 AM - Globe NewsWire
Artelo publishes study supporting ART26.12 pain treatment
April 20, 2026 7:51 AM - StreetInsider
Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile
April 20, 2026 7:50 AM - Globe NewsWire
Form 424B3 ARTELO BIOSCIENCES, INC.
April 16, 2026 8:01 AM - SEC Filing
Form EFFECT ARTELO BIOSCIENCES, INC.
April 16, 2026 6:06 AM - SEC Filing
Artelo Biosciences (ARTL) files for 9.82M share offering by selling stockholders
April 7, 2026 4:21 PM - StreetInsider
Form S-1 ARTELO BIOSCIENCES, INC.
April 7, 2026 4:19 PM - SEC Filing
Form 8-K ARTELO BIOSCIENCES, INC. For: Apr 06
April 7, 2026 12:47 PM - SEC Filing
Artelo Biosciences regains NASDAQ listing compliance
April 7, 2026 12:28 PM - StreetInsider
Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements
April 7, 2026 12:27 PM - Globe NewsWire
Form D ARTELO BIOSCIENCES, INC.
April 6, 2026 12:58 PM - SEC Filing
Form SCHEDULE 13G ARTELO BIOSCIENCES, INC. Filed by: INTRACOASTAL CAPITAL, LLC
April 3, 2026 4:47 PM - SEC Filing
Form EFFECT ARTELO BIOSCIENCES, INC.
March 31, 2026 6:19 AM - SEC Filing
Form 8-K ARTELO BIOSCIENCES, INC. For: Mar 27
March 30, 2026 5:44 PM - SEC Filing
Artelo Biosciences completes $11 million private placement
March 30, 2026 4:46 PM - StreetInsider
Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
March 30, 2026 4:46 PM - Globe NewsWire
Form D ARTELO BIOSCIENCES, INC.
March 27, 2026 5:01 PM - SEC Filing
Form D ARTELO BIOSCIENCES, INC.
March 27, 2026 5:01 PM - SEC Filing
Form D ARTELO BIOSCIENCES, INC.
March 27, 2026 5:00 PM - SEC Filing
Artelo Biosciences raises $11 million in private placement
March 27, 2026 10:40 AM - StreetInsider
Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
March 27, 2026 10:40 AM - Globe NewsWire
Form RW ARTELO BIOSCIENCES, INC.
March 27, 2026 8:01 AM - SEC Filing
Form 8-K ARTELO BIOSCIENCES, INC. For: Mar 20
March 26, 2026 5:00 PM - SEC Filing
Form EFFECT ARTELO BIOSCIENCES, INC.
March 26, 2026 6:07 AM - SEC Filing
Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments
March 25, 2026 4:05 PM - Globe NewsWire
Artelo Biosciences enters glaucoma market via funded study
March 25, 2026 7:31 AM - StreetInsider
Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength
March 25, 2026 7:31 AM - StreetInsider
Form S-1 ARTELO BIOSCIENCES, INC.
March 24, 2026 5:33 PM - SEC Filing
Form S-1/A ARTELO BIOSCIENCES, INC.
March 24, 2026 5:14 PM - SEC Filing
Form S-1/A ARTELO BIOSCIENCES, INC.
March 23, 2026 5:25 PM - SEC Filing
Form S-1 ARTELO BIOSCIENCES, INC.
March 20, 2026 5:18 PM - SEC Filing
Form 8-K ARTELO BIOSCIENCES, INC. For: Mar 12
March 18, 2026 5:02 PM - SEC Filing
Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum
March 18, 2026 10:42 AM - StreetInsider
Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study
March 18, 2026 8:07 AM - StreetInsider
Artelo enters glaucoma study agreement with Belfast Health Trust
March 18, 2026 7:43 AM - StreetInsider
Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients
March 18, 2026 7:41 AM - Globe NewsWire
Form 8-K ARTELO BIOSCIENCES, INC. For: Mar 17
March 17, 2026 4:46 PM - SEC Filing
Full Article List
